海思科：多项药物临床试验获批准

Group 1 - The company, Haisco (002653.SZ), announced that its subsidiary, Shanghai Haisco Shengnuo Pharmaceutical Technology Co., Ltd., has received the Clinical Trial Approval Notice from the National Medical Products Administration [1] - The approved clinical trials include HSK45019 tablets, HSK50042 tablets, injectable HSK55718, and HSK36357 capsules, targeting indications such as inflammatory bowel disease, respiratory diseases, acute pain, and muscular dystrophy [1]